Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/221187
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lázaro, J. | - |
dc.contributor.author | Alcon, Clara | - |
dc.contributor.author | Lissat, A. | - |
dc.contributor.author | Montero, J. | - |
dc.contributor.author | Eckert, C. | - |
dc.date.accessioned | 2025-05-23T12:58:55Z | - |
dc.date.available | 2025-05-23T12:58:55Z | - |
dc.date.issued | 2024-05-10 | - |
dc.identifier.issn | 0300-8630 | - |
dc.identifier.uri | https://hdl.handle.net/2445/221187 | - |
dc.description.abstract | Resistance to blinatumomab (CD19-CD3 BiTE) is a significant obstacle in the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), prompting the investigation of novel drug combinations. We aimed to generate an "in vitro" model capable of identifying synergistic combinations to enhance blinatumomab's efficacy in BCP-ALL treatment. Drug response profiling used annexin V/propidium iodide/CD3 staining and flow cytometry analysis in 28 patient samples and 4 cell lines. Co-cultured with healthy donor T-cells, samples were treated for 24h with blinatumomab and/or other inhibitors. Differential sensitivity to blinatumomab was observed among patient samples and cell lines. Idelalisib (tyrosin kinase inhibitor; TKi) combined with blinatumomab exhibited potential antagonistic effects. Birinapant (SMAC mimetic) and venetoclax (BCL2 inhibitor) demonstrated increased efficacy in BCP-ALL cell lines, displaying synergistic potential with blinatumomab. Our findings support TKi and SMAC mimetics' immunomodulatory effects, in accordance to prior anti-CD19 CAR T cell reports. Venetoclax emerges as a promising candidate for combination therapy against blinatumomab resistance. | - |
dc.format.extent | 2 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Georg Thieme Verlag | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1055/s-0044-1786596 | - |
dc.relation.ispartof | Klinische Pädiatrie, 2024, vol. 236, num.3 | - |
dc.relation.uri | https://doi.org/10.1055/s-0044-1786596 | - |
dc.rights | (c) Georg Thieme Verlag, 2024 | - |
dc.source | Articles publicats en revistes (Biomedicina) | - |
dc.subject.classification | Leucèmia | - |
dc.subject.classification | Leucèmia limfocítica crònica | - |
dc.subject.classification | Medicaments | - |
dc.subject.other | Leukemia | - |
dc.subject.other | Chronic lymphocytic leukemia | - |
dc.subject.other | Drugs | - |
dc.title | Exploring Synergistic Approaches to Enhance Blinatumomab's Efficacy in Acute Lymphoblastic Leukemia | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 750714 | - |
dc.date.updated | 2025-05-23T12:58:55Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
867680.pdf | 375.98 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.